Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 4789279, 9 pages
http://dx.doi.org/10.1155/2016/4789279
Review Article

Monocyte Activation in Immunopathology: Cellular Test for Development of Diagnostics and Therapy

1Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
2Institute of General Pathology and Pathophysiology, Moscow 125315, Russia
3Institute for Atherosclerosis Research, Skolkovo Innovation Center, Moscow 121609, Russia
4Department of Biophysics, Biological Faculty, Moscow State University, Moscow 119991, Russia

Received 2 October 2015; Revised 20 December 2015; Accepted 21 December 2015

Academic Editor: Oscar Bottasso

Copyright © 2016 Ekaterina A. Ivanova and Alexander N. Orekhov. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Biswas and A. Mantovani, “Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm,” Nature Immunology, vol. 11, no. 10, pp. 889–896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Peled and E. A. Fisher, “Dynamic aspects of macrophage polarization during atherosclerosis progression and regression,” Frontiers in Immunology, vol. 5, no. 579, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Feig, S. Parathath, J. X. Rong et al., “Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques,” Circulation, vol. 123, no. 9, pp. 989–998, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Feig, J. X. Rong, R. Shamir et al., “HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7166–7171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Weber and H. Noels, “Atherosclerosis: current pathogenesis and therapeutic options,” Nature Medicine, vol. 17, no. 11, pp. 1410–1422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. K. Hansson and A. Hermansson, “The immune system in atherosclerosis,” Nature Immunology, vol. 12, no. 3, pp. 204–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Klingenberg and G. K. Hansson, “Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies,” European Heart Journal, vol. 30, no. 23, pp. 2838–2844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Beaglehole and R. Bonita, “Global public health: a scorecard,” The Lancet, vol. 372, no. 9654, pp. 1988–1996, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. F. Fries, “Strategies for reduction of morbidity,” The American Journal of Clinical Nutrition, vol. 55, supplement 6, pp. 1257S–1262S, 1992. View at Google Scholar
  12. B. Mostert, A. M. Sieuwerts, J. Kraan et al., “Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients,” Annals of Oncology, vol. 26, no. 3, pp. 510–516, 2015. View at Publisher · View at Google Scholar
  13. B. Mostert, A. M. Sieuwerts, J. Bolt-de Vries et al., “mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients,” Molecular Oncology, vol. 9, no. 4, pp. 920–932, 2015. View at Publisher · View at Google Scholar
  14. V. Hofman, M. Ilie, E. Long et al., “Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls,” Current Molecular Medicine, vol. 14, no. 4, pp. 440–456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Polzer, G. Medoro, S. Pasch et al., “Molecular profiling of single circulating tumor cells with diagnostic intention,” EMBO Molecular Medicine, vol. 6, no. 11, pp. 1371–1386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Reynés, R. Díaz-Rúa, M. Cifre, P. Oliver, and A. Palou, “Peripheral blood mononuclear cells as a potential source of biomarkers to test the efficacy of weight-loss strategies,” Obesity, vol. 23, no. 1, pp. 28–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. K. L. Bentley-Hewitt, R. K.-Y. Chen, R. E. Lill et al., “Consumption of selenium-enriched broccoli increases cytokine production in human peripheral blood mononuclear cells stimulated ex vivo, a preliminary human intervention study,” Molecular Nutrition & Food Research, vol. 58, no. 12, pp. 2350–2357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Bordignon, F. Palamara, G. Altomonte et al., “A laboratory test based on determination of cytokine profiles: a promising assay to identify exposition to contact allergens and predict the clinical outcome in occupational allergic contact dermatitis,” BMC Immunology, vol. 16, article 4, 2015. View at Publisher · View at Google Scholar
  19. M. M. Venkataswamy, S. N. Madhusudana, S. S. Sanyal et al., “Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes,” Clinical and Experimental Vaccine Research, vol. 4, no. 1, pp. 68–74, 2015. View at Publisher · View at Google Scholar
  20. M. G. Cardenas-Mondragon, G. Vallejo-Flores, J. Delgado-Dominguez et al., “Preeclampsia is associated with lower production of vascular endothelial growth factor by peripheral blood mononuclear cells,” Archives of Medical Research, vol. 45, no. 7, pp. 561–569, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Jenny, M. Klieber, D. Zaknun et al., “In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors,” Inflammation Research, vol. 60, no. 2, pp. 127–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. N. Orekhov, I. A. Sobenin, M. A. Gavrilin et al., “Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy,” Current Pharmaceutical Design, vol. 21, no. 9, pp. 1172–1179, 2015. View at Publisher · View at Google Scholar
  23. W. E. Hellings, W. Peeters, F. L. Moll, and G. Pasterkamp, “From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization,” Trends in Cardiovascular Medicine, vol. 17, no. 5, pp. 162–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Schaar, J. E. Muller, E. Falk et al., “Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece,” European Heart Journal, vol. 25, no. 12, pp. 1077–1082, 2004. View at Google Scholar
  25. N. V. Serbina, T. Jia, T. M. Hohl, and E. G. Pamer, “Monocyte-mediated defense against microbial pathogens,” Annual Review of Immunology, vol. 26, pp. 421–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. van Furth and Z. A. Cohn, “The origin and kinetics of mononuclear phagocytes,” The Journal of Experimental Medicine, vol. 128, no. 3, pp. 415–435, 1968. View at Publisher · View at Google Scholar · View at Scopus
  27. M. H. Sieweke and J. E. Allen, “Beyond stem cells: self-renewal of differentiated macrophages,” Science, vol. 342, no. 6161, Article ID 1242974, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. N. P. Hurst and G. Nuki, “Evidence for defect of complement-mediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis,” British Medical Journal, vol. 282, no. 6282, pp. 2081–2083, 1981. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Meuret and G. Hoffmann, “Monocyte kinetic studies in normal and disease states,” British Journal of Haematology, vol. 24, no. 3, pp. 275–285, 1973. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Meuret, J. Bammert, and G. Hoffmann, “Kinetics of human monocytopoiesis,” Blood, vol. 44, no. 6, pp. 801–816, 1974. View at Google Scholar · View at Scopus
  31. P. R. Taylor and S. Gordon, “Monocyte heterogeneity and innate immunity,” Immunity, vol. 19, no. 1, pp. 2–4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Geissmann, S. Gordon, D. A. Hume, A. M. Mowat, and G. J. Randolph, “Unravelling mononuclear phagocyte heterogeneity,” Nature Reviews Immunology, vol. 10, no. 6, pp. 453–460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. J. Jenkins and D. A. Hume, “Homeostasis in the mononuclear phagocyte system,” Trends in Immunology, vol. 35, no. 8, pp. 358–367, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Bartocci, D. S. Mastrogiannis, G. Migliorati, R. J. Stockert, A. W. Wolkoff, and E. R. Stanley, “Macrophages specifically regulate the concentration of their own growth factor in the circulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 17, pp. 6179–6183, 1987. View at Publisher · View at Google Scholar · View at Scopus
  35. J. C. Gasson, “Molecular physiology of granulocyte-macrophage colony-stimulating factor,” Blood, vol. 77, no. 6, pp. 1131–1145, 1991. View at Google Scholar · View at Scopus
  36. P. J. Murray, J. E. Allen, S. K. Biswas et al., “Macrophage activation and polarization: nomenclature and experimental guidelines,” Immunity, vol. 41, no. 1, pp. 14–20, 2014. View at Publisher · View at Google Scholar
  37. S. Gordon and F. O. Martinez, “Alternative activation of macrophages: mechanism and functions,” Immunity, vol. 32, no. 5, pp. 593–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, “M-1/M-2 macrophages and the Th1/Th2 paradigm,” The Journal of Immunology, vol. 164, no. 12, pp. 6166–6173, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Gordon and P. R. Taylor, “Monocyte and macrophage heterogeneity,” Nature Reviews Immunology, vol. 5, no. 12, pp. 953–964, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Gratchev, K. Schledzewski, P. Guillot, and S. Goerdt, “Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing,” Skin Pharmacology and Applied Skin Physiology, vol. 14, no. 5, pp. 272–279, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Gordon, “The macrophage,” BioEssays, vol. 17, no. 11, pp. 977–986, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. F. De Paoli, B. Staels, and G. Chinetti-Gbaguidi, “Macrophage phenotypes and their modulation in atherosclerosis,” Circulation Journal, vol. 78, no. 8, pp. 1775–1781, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. R. N. Hanna, I. Shaked, H. G. Hubbeling et al., “NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis,” Circulation Research, vol. 110, no. 3, pp. 416–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. J. Davies, “Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995,” Circulation, vol. 94, no. 8, pp. 2013–2020, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. H. C. Stary, A. B. Chandler, R. E. Dinsmore et al., “A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association,” Circulation, vol. 92, no. 5, pp. 1355–1374, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Rojas, J. Salazar, M. S. Martínez et al., “Macrophage heterogeneity and plasticity: impact of macrophage biomarkers on atherosclerosis,” Scientifica, vol. 2015, Article ID 851252, 17 pages, 2015. View at Publisher · View at Google Scholar
  47. T. J. Koh and L. A. DiPietro, “Inflammation and wound healing: the role of the macrophage,” Expert Reviews in Molecular Medicine, vol. 13, article e23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. B. D. Fleming and D. M. Mosser, “Regulatory macrophages: setting the threshold for therapy,” European Journal of Immunology, vol. 41, no. 9, pp. 2498–2502, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Gratchev, J. Kzhyshkowska, K. Duperrier, J. Utikal, F. W. Velten, and S. Goerdt, “The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells,” Scandinavian Journal of Immunology, vol. 60, no. 3, pp. 233–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Kodelja, C. Müller, O. Politz, N. Hakij, C. E. Orfanos, and S. Goerdt, “Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1α with a Th2- associated expression pattern,” The Journal of Immunology, vol. 160, no. 3, pp. 1411–1418, 1998. View at Google Scholar · View at Scopus
  51. O. Politz, A. Gratchev, P. A. G. McCourt et al., “Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues,” The Biochemical Journal, vol. 362, no. 1, pp. 155–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. M. Tiemessen, A. L. Jagger, H. G. Evans, M. J. C. van Herwijnen, S. John, and L. S. Taams, “CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19446–19451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Martinon, K. Burns, and J. Tschopp, “The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β,” Molecular Cell, vol. 10, no. 2, pp. 417–426, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. K. J. Moore and I. Tabas, “Macrophages in the pathogenesis of atherosclerosis,” Cell, vol. 145, no. 3, pp. 341–355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Sarkar, S. Mitra, S. Mehta, R. Raices, and M. D. Wewers, “Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1,” PLoS ONE, vol. 4, no. 9, Article ID e7140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. A. Gavrilin, S. Mitra, S. Seshadri et al., “Pyrin critical to macrophage IL-1β response to Francisella challenge,” The Journal of Immunology, vol. 182, no. 12, pp. 7982–7989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Gavrilin, D. H. A. Abdelaziz, M. Mostafa et al., “Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia,” Journal of Immunology, vol. 188, no. 7, pp. 3469–3477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, pp. 197–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Duewell, H. Kono, K. J. Rayner et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, vol. 464, no. 7293, pp. 1357–1361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. V. V. Valtonen, “Infection as a risk factor for infarction and atherosclerosis,” Annals of Medicine, vol. 23, no. 5, pp. 539–543, 1991. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Luque, M. M. Turu, N. Rovira, J. O. Juan-Babot, M. Slevin, and J. Krupinski, “Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae,” Frontiers in Bioscience, vol. 4, no. 7, pp. 2423–2432, 2012. View at Google Scholar · View at Scopus
  63. M. Charakida and D. Tousoulis, “Infections and atheromatous plaque: current therapeutic implications,” Current Pharmaceutical Design, vol. 19, no. 9, pp. 1638–1650, 2013. View at Google Scholar · View at Scopus
  64. E. Krishnan, “Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout,” Rheumatology, vol. 49, no. 7, Article ID keq037, pp. 1229–1238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Razani, C. Feng, T. Coleman et al., “Autophagy links inflammasomes to atherosclerotic progression,” Cell Metabolism, vol. 15, no. 4, pp. 534–544, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. E. F. Strasser and R. Eckstein, “Optimization of leukocyte collection and monocyte isolation for dendritic cell culture,” Transfusion Medicine Reviews, vol. 24, no. 2, pp. 130–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. S. B. Clarkson and P. A. Ory, “CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes,” The Journal of Experimental Medicine, vol. 167, no. 2, pp. 408–420, 1988. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Krause, A. Pohl, C. Pohl et al., “Ex vivo investigation of blood monocyte and platelet behaviour in pigs maintained on an atherogenic diet,” Experimental and Toxicologic Pathology, vol. 44, no. 3, pp. 144–146, 1992. View at Publisher · View at Google Scholar · View at Scopus
  69. F. P. Bell and R. G. Gerrity, “Evidence for an altered lipid metabolic state in circulating blood monocytes under conditions of hyperlipemia in swine and its implications in arterial lipid metabolism,” Arteriosclerosis and Thrombosis, vol. 12, no. 2, pp. 155–162, 1992. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Gratchev, P. Guillot, N. Hakiy et al., “Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein βIG-H3,” Scandinavian Journal of Immunology, vol. 53, no. 4, pp. 386–392, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Gratchev, J. Kzhyshkowska, K. Köthe et al., “Mφ1 and Mφ2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals,” Immunobiology, vol. 211, no. 6–8, pp. 473–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., “CSF-1R inhibition alters macrophage polarization and blocks glioma progression,” Nature Medicine, vol. 19, no. 10, pp. 1264–1272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, “Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro,” Atherosclerosis, vol. 135, no. 1, pp. 19–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  75. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, “Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta,” Atherosclerosis, vol. 130, no. 1-2, pp. 133–142, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. E. J. Mills, B. Rachlis, P. Wu, P. J. Devereaux, P. Arora, and D. Perri, “Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients,” Journal of the American College of Cardiology, vol. 52, no. 22, pp. 1769–1781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Hirayama and T. Miida, “Small dense LDL: an emerging risk factor for cardiovascular disease,” Clinica Chimica Acta, vol. 414, pp. 215–224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Steinberg, S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum, “Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity,” The New England Journal of Medicine, vol. 320, no. 14, pp. 915–924, 1989. View at Publisher · View at Google Scholar · View at Scopus
  79. A. N. Orekhov, V. V. Tertov, and D. N. Mukhin, “Desialylated low density lipoprotein—naturally occurring modified lipoprotein with atherogenic potency,” Atherosclerosis, vol. 86, no. 2-3, pp. 153–161, 1991. View at Publisher · View at Google Scholar · View at Scopus
  80. A. N. Orekhov, V. V. Tertov, A. E. Kabakov, I. Y. Adamova, S. N. Pokrovsky, and V. N. Smirnov, “Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation,” Arteriosclerosis and Thrombosis, vol. 11, no. 2, pp. 316–326, 1991. View at Publisher · View at Google Scholar · View at Scopus
  81. E. I. Chazov, A. N. Orekhov, N. V. Perova et al., “Atherogenicity of blood serum from patients with coronary heart disease,” The Lancet, vol. 328, no. 8507, pp. 595–598, 1986. View at Publisher · View at Google Scholar · View at Scopus
  82. A. N. Orekhov, V. V. Tertov, K. A. Khashimov, S. S. Kudryashov, and V. N. Smirnov, “Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells,” The American Journal of Cardiology, vol. 59, no. 5, pp. 495–496, 1987. View at Google Scholar
  83. S. E. Akopov, A. N. Orekhov, V. V. Tertov, K. A. Khashimov, E. S. Gabrielyan, and V. N. Smirnov, “Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta The effect of calcium antagonists,” Atherosclerosis, vol. 72, no. 2-3, pp. 245–248, 1988. View at Publisher · View at Google Scholar · View at Scopus
  84. A. N. Orekhov, V. V. Tertov, S. A. Kudryashov, K. A. Khashimov, and V. N. Smirnov, “Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents,” Atherosclerosis, vol. 60, no. 2, pp. 101–110, 1986. View at Publisher · View at Google Scholar · View at Scopus